megakaryocytic progenitor cells

also known as MPs

Developed for: thrombocytopenia
Investigated by: Academy Military Medical Science, China · Guangdong Provincial People's Hospital · Guangzhou First People's Hospital · Guangzhou General Hospital of Guangzhou Military Command · Huazhong University of Science and Technology · Nanfang Hospital, Southern Medical University
+5 more
· Peking University People's Hospital · Southern Medical University, China · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sun Yat-sen University · Third Affiliated Hospital, Sun Yat-Sen University

today NCT02241031 · Ph 2/3

2015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2/3	NCT02241031	Sep 2014 → Sep 2016	thrombocytopenia	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	megakaryocytic progenitor cells	“ex vivo generated megakaryocytic progenitor cells (MPs)” NCT02241031 ↗
Known as	MPs	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02241031 ↗
Modality	Cell therapy	“ex vivo generated megakaryocytic progenitor cells (MPs)” NCT02241031 ↗
Route	Intravenous	“MPs will be intravenously infused within 48 hours after chemotherapy.” NCT02241031 ↗